Direct Discrimination of Quantum States by the Human Eye
1 other identifier
interventional
50
1 country
1
Brief Summary
Age-related macular degeneration (AMD), is a debilitating eye disease that causes a loss of central vision. The prevalence of AMD increases exponentially with age and causes a significant impact through both medical expenses and the social and economic costs associated with vision loss. AMD is the global leading cause of blindness among people over the age of 60. Detection of this eye disease at early stages coupled with prompt treatment can prevent vision loss; however, modern diagnosis methods are ineffective at diagnosis of AMD before vision loss occurs. While a range of available treatment options has been effective at slowing vision loss due to AMD, no treatment exists which can recover lost vision. The investigators propose to apply tools developed in quantum information science to diagnose AMD before vision has been affected, drastically improving health outcomes for patients with AMD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jun 2023
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 31, 2023
CompletedFirst Posted
Study publicly available on registry
June 22, 2023
CompletedStudy Start
First participant enrolled
June 26, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 1, 2029
March 18, 2026
March 1, 2026
6 years
May 31, 2023
March 16, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Perception of the structured light
Assessment of the participant's ability to see the entoptic phenomena created using the structured light (SL) - orbital angular momentum (OAM) coupled polarized light. Various SL vortex and radial patterns will be projected using the custom research-based laser optical setup
Approximately 10 minutes, Screening and Training day (Session 1)
Radius of the radial retinal polarizer
Calculation of the radius of the central obstruction. From a total of 14 reversal trials, the six last values of the mask size will be used for the calculation of the threshold mask size mean (r mean). The standard deviation will be computed from the variance of these last six trials
Approximately 30 minutes, on the completion of the study (Session 6)
Secondary Outcomes (5)
Thickness of retina and retinal layers
Approximately 10 minutes, Screening and Training day (Session 1)
Contrast sensitivity
Approximately 5 minutes, Screening and Training day (Session 1)
Fundus photography
Approximately 5 minutes, Screening and Training day (Session 1)
Ocular biometry measurement
Approximately 5 minutes, Screening and Training day (Session 1)
Macular pigment optical density measurement
Approximately 10 minutes, Screening and Training day (Sessions 1 and 2)
Study Arms (1)
Participants with Age-Related Macular Degeneration
EXPERIMENTALConducting the psychophysical task on the perception of OAM-coupled polarized light
Interventions
Conducting the psychophysical task on the perception of OAM-coupled polarized light created using the experimental setup - Structured Light Imaging Microscopy (SLIM). Four types of vortex orbital angular momentum, differing by the number of fringes l=5;10; 15;20, will be presented for 0.5s per trial during which an azimuthally varying entoptic profile rotated clockwise or counterclockwise. A circular mask with a varying radius will be placed at fixation, thus the task will be performed at varying eccentricities. Circular obstruction of the area will be achieved due to the high refresh-rate structured light modulator. The threshold mask size will be changed by a 2up/1down staircase method (71% accuracy for the estimation of mask size).
Eligibility Criteria
You may qualify if:
- Participants who are clinically diagnosed with a vision disease affecting their macula
- Older adults who are matched for age.
- Participants who are clinically diagnosed with glaucoma
- Participants who have normal vision.
- One aged-matched control with normal vision will be recruited for each of the diagnosed groups (born in the same year).
You may not qualify if:
- Participants with any additional eye diagnosis or condition
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Centre for Eye and Vision Researchlead
- University of Waterloocollaborator
- The Hong Kong Polytechnic Universitycollaborator
Study Sites (1)
Centre for Eye and Vision Research Limited
Hong Kong, Guangdong, 00000, Hong Kong
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Benjamin Thompson, PhD
Centre for Eye and Vision Research
- STUDY DIRECTOR
Mukhit Kulmaganbetov, MD, PhD
Centre for Eye and Vision Research
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 31, 2023
First Posted
June 22, 2023
Study Start
June 26, 2023
Primary Completion (Estimated)
July 1, 2029
Study Completion (Estimated)
October 1, 2029
Last Updated
March 18, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- After the publication of study results for an indefinite period.
- Access Criteria
- Upon reasonable request and approved by the study principal investigator.
Anonymized data will be shared on request